Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 31, 1998

Primary Completion Date

November 30, 1998

Study Completion Date

December 31, 1998

Conditions
CancerGraft-Versus-Host Disease
Interventions
DRUG

MEDI-507

0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of normal saline on Days 16, 23, 30, and 37.

DRUG

MEDI-507

0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of MEDI-507 on Days 16, 23, 30, and 37.

Trial Locations (10)

15224

Western Pennsylvania Hospital - Western Pennsylvania Cancer Center, Pittsburgh

48109

University of Michigan Hospital, Ann Arbor

63110

Washington University Medical Center, St Louis

68198

University of Nebraska Medical Center, Omaha

73104

University Hospital-University of Oklahoma, Oklahoma City

75246

Baylor University Medical Center, Dallas

77030

M.D. Anderson Cancer Center, Houston

78229

South Texas Cancer Institute at Methodist Hospital, San Antonio

80262

University of Colorado Health Sciences Center, Denver

91010

City of Hope National Medical Center, Duarte

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MedImmune LLC

INDUSTRY